Medicenna Therapeutics (TSE:MDNA) Hits New 12-Month Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low during trading on Monday . The stock traded as low as C$0.38 and last traded at C$0.40, with a volume of 72738 shares. The stock had previously closed at C$0.41.

Medicenna Therapeutics Stock Performance

The stock has a market capitalization of C$32.95 million, a price-to-earnings ratio of -2.63 and a beta of 2.89. The company has a 50 day simple moving average of C$0.50 and a 200-day simple moving average of C$0.73. The company has a quick ratio of 4.65, a current ratio of 1.52 and a debt-to-equity ratio of 4.79.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. As a group, equities research analysts expect that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.